NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Ownership - Who owns 4d Molecular Therapeutics?

Insider buying vs selling

Have 4d Molecular Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Scott BizilyChief Legal Officer2025-10-241,084$6.49
$7.04kBuy
Scott BizilyChief Legal Officer2025-10-242,678$12.00
$32.14kSell
Scott BizilyChief Legal Officer2025-10-161,635$4.14
$6.77kBuy
Scott BizilyChief Legal Officer2025-10-161,635$10.17
$16.63kSell
Scott BizilyChief Legal Officer2025-10-092,408$10.00
$24.08kSell
Scott BizilyChief Legal Officer2025-09-232,407$8.00
$19.26kSell

1 of 1

FDMT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FDMT insiders and whales buy or sell their stock.

FDMT Shareholders

What type of owners hold 4d Molecular Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc9.91%4,629,289$48.61MInstitution
Ra Capital Management LP9.77%4,563,211$47.91MInstitution
Ra Capital Management LP9.77%4,563,211$47.91MInsider
Viking Global Investors LP9.10%4,247,914$44.60MInsider
Goldman Sachs Group Inc8.91%4,159,264$43.67MInstitution
Blackrock Inc8.59%4,010,755$42.11MInstitution
Vanguard Group Inc5.86%2,736,671$28.74MInstitution
Novo Holdings A4.28%2,000,000$21.00MInstitution
Janus Henderson Group PLC3.76%1,754,410$18.42MInstitution
Federated Hermes Inc3.57%1,667,338$17.51MInstitution

1 of 3

FDMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FDMT70.71%22.21%Net SellingNet Selling
GOSS76.58%14.90%Net BuyingNet Buying
CRVS55.95%41.58%Net Buying
PRTA49.39%50.61%Net Selling
NAGE17.10%82.90%Net Buying

4d Molecular Therapeutics Stock Ownership FAQ

Who owns 4d Molecular Therapeutics?

4d Molecular Therapeutics (NASDAQ: FDMT) is owned by 70.71% institutional shareholders, 22.21% 4d Molecular Therapeutics insiders, and 7.08% retail investors. Ra Capital Management LP is the largest individual 4d Molecular Therapeutics shareholder, owning 4.56M shares representing 7.99% of the company. Ra Capital Management LP's 4d Molecular Therapeutics shares are currently valued at $46.41M.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.